LRRK2-IN-1

Chemical Formula: $C_{31}H_{38}N_8O_3$ Molecular Weight: 570.69

Category	Parameter	Description
Compound	Name	LRRK2-IN-1
	Citation	Nat. Chem. Biol. 2011 , 7, 203-205.
	Chemical descriptors	O=C1C2=C(C=CC=C2)N(C)C3=NC(NC4=C(OC)C=C(C(N5CCC(N6CCN(C)CC6)CC5)=O) C=C4)=NC=C3N1C
	Chemical name	2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl)phenyl)amino)-5,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one
	Availability	MERCK4Biosciences http://www.merck-chemicals.com/life-science-research/lrrk2-in-1/EMD_BIO-438193/p_uuid?WT_oss=438193&WT_oss_r=1
<i>In vitro</i> profiling	Target (potency)	LRRK2 (20 nM K_d in Ambit binding assay, 3 nM IC_{50} in Invitrogen biochemical assay, 13 nM IC_{50} in Dundee biochemical assay)
III VIIIO PIOIIIIII		$\textbf{LRRK2(G2019S)}$ (11 nM K_d in Ambit binding assay, 4 nM IC $_{50}$ in Invitrogen biochemical assay, 6 nM IC $_{50}$ in Dundee biochemical assay)
	Additional Target (potency)	MAPK7 (28 nM K _d in Ambit binding assay)
		DCLK2 (16 nM K_d in Ambit binding assay, 45 nM IC_{50} in Invitrogen biochemical assay, 210 nM IC_{50} in Dundee biochemical assay)
	Selectivity	
	Potential reactivity None to our knowledge	None to our knowledge
	SAR	
	Mechanism of inhibition	ATP-competitive
	Structure of target-probe complex	

	Validation of cellular target	LRRK2-IN-1 dose-dependently inhibited LRRK2, LRRK2(G2019S) at 1-3 μ M in HEK29 cells.
		LRRK2-IN-1 dose-dependently inhibited LRRK2 at 1-3 μM in human lymphoblastoid or derived from a control individual.
Cellular profiling		LRRK2-IN-1 dose-dependently inhibited LRRK2(G2019S) at 1-3 μM in a Parkinson's disease patient homozygous.
Celidial profiling		LRRK2-IN-1 dose-dependently inhibited LRRK2 at 1-3 μM in human derived neuroblastoma SHSY5Y cells and mouse Swiss 3T3 cells.
		LRRK2-IN-1 dose-dependently inhibited MAPK7 autophosphorylation induced by EGI HeLa cells with IC50 of 160 nM.
		Compound phenotypes were compared to literature. The cellular effects were correlate with <i>in vitro</i> biochemical activities.
	Validation of cellular specificity	
Pharmacodynamics		Poor BBB property.
Pharmacokinetics		$T_{1/2}$ = 4.47 hours, CL = 5.6 (mL/min/Kg), Vss = 1.7 (L/Kg), F = 49.3%
	CIN	NO ₂ O DIEA, Dioxane CI N Me Fe/HOAc 50 °C CI N CO ₂ Et
Synthetic scheme	N N N	O Mel/NaH N N N N N N N N N N N N N N N N N N
	2	Pd ₂ (dba) ₃ (6% mol) K ₂ CO ₃ (3.0 eq.) t-BuOH/100 °C